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Abstract
Background: It has been recognized that despite previous stability some patients with idiopathic pulmonary
fibrosis (IPF) experience acute clinical deteriorations called acute exacerbations of idiopathic pulmonary fibrosis
(AEX-IPF). We hypothesized that pulmonary infection can be excluded based on clinical and laboratory data and
that bronchoscopy with BAL is not mandatory in the diagnostic work-up of suspected AEX-IPF.
Methods: In this retrospective study we identified patients with acute respiratory failure who were evaluated for
AEX-IPF at the Cleveland Clinic between January 2002 and December 2011. Univariate and multivariate analysis
were performed with predefined risk factors and final diagnosis of AEX-IPF and pulmonary infection. All tests were
performed at a significance level of 0.05.
Results: A total of 77 patients met the study inclusion criteria. Of these patients 47 (61 %) were diagnosed with
AEX-IPF. Bronchoscopy was more likely to be performed in patients who were on cytotoxic medications (p < 0.05).
In most cases the diagnosis of AEX-IPF versus pulmonary infection was based on combination of other microbiological,
clinical, radiologic data and clinical judgment. A total of 10 patients out of 14 (71 %) with a final diagnosis of pulmonary
infection were on steroids on admission versus 21 out of 63 patients (33 %) with other final diagnosis (p = 0.024, OR
7.817, 95 % CI 1.31–46.64).
Conclusions: Exclusion of infection in our IPF patient cohort was mostly based on factors other than diagnostic
bronchoscopy with BAL. Based on our results we suggested an algorithm for management of IPF patients presenting
with acute respiratory failure.
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Background
Idiopathic pulmonary fibrosis (IPF) is the most common
form of idiopathic interstitial pneumonia. It has been rec-
ognized that some patients with IPF experience acute clin-
ical deteriorations, despite previous stability. Most of these
deteriorations are idiopathic; others are secondary to infec-
tion, left heart failure, pulmonary embolism, pneumo-
thorax and other identifiable causes of acute lung injury.
These episodes of idiopathic acute deteriorations have been
termed acute exacerbations of IPF (AEX-IPF). Diagnostic
consensus criteria for AEX-IPF were suggested by Collard
et al. in 2007 [1] and include: previous or concurrent diag-
nosis of IPF, unexplained worsening or development of
dyspnea within the past 30 days, specific high resolution
chest computed tomography (CT) pattern and no evidence
of infection in the absence of alternative causes that are
specifically mentioned in the consensus statement.
According to these criteria, AEX-IPF can only be diag-
nosed if there is no evidence of pulmonary infection by
endotracheal aspirate or bronchoalveolar lavage (BAL).
Evaluation of samples should include studies for routine
bacterial organisms, opportunistic pathogens such as
pneumocystis jiroveci (PJP), and common viral pathogens
including influenza A and B, parainfluenza 1–4, respira-
tory syncytial virus A and B, human metapneumovirus,
adenovirus and coronaviruses. Those patients who have
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no endotracheal aspirate or BAL available are classified as
having “suspected acute exacerbation of IPF”.
A study by Wootton et al. [2] did not detect viral infec-
tion in most cases of AEX-IPF. In this study four of 43 BAL
samples from AEX-IPF patients were positive for respira-
tory viruses and 15 for non-respiratory viruses compared to
no viral detection in stable IPF controls. This study sug-
gested that isolation of these viruses has no proven clinical
significance, so BAL viral studies might not be helpful in
management of these patients [2]. AEX-IPF cases occur
more commonly in winter and spring, suggesting that some
of them might have unidentified infections etiology, even
despite extensive microbiological workup [3]. On the other
hand, some patients with suspected AEX-IPF have micro-
biological evidence of infection but also have clinical and
imaging characteristics of AEX-IPF [4]. Completing the
course of broad spectrum antibiotics might be reasonable
even if there is a low suspicion of pulmonary infection and
AEX-IPF is the working diagnosis especially if there is clin-
ical improvement. Procalcitonin guided antibiotic use has
been tested in various respiratory infections, including IPF,
and was shown to reduce the antibiotic exposure in AEX-
IPF patients [5]. This strategy is not routinely recom-
mended and should be further explored.
In a recent proposal by Johannson and Collard, authors
also question the mandatory role of BAL in the diagnostic
workup of AEX-IPF patients, considering poor sensitivity
of microbiological tests and the risk of worsening hypox-
emia with bronchoscopy in non-intubated patients with
baseline high oxygen requirements [6]. Some risk factors
favor the diagnosis of AEX-IPF, such as obesity, subacutely
worsening dyspnea, decline in forced vital capacity and
pulmonary hypertension [7,8]. Identified risk factors should
be incorporated into clinical decision tools and treatment
algorithms.
In this study, we hypothesize that pulmonary infection
can be excluded based on clinical and laboratory data
and that bronchoscopy with BAL is not mandatory in
the diagnostic work-up of patient with suspected AEX-
IPF. We also looked for risk factors and patient charac-
teristics that might help to guide treatment decisions.
Methods
This retrospective study identified patients with idiopathic
pulmonary fibrosis and acute respiratory failure who were
evaluated for AEX-IPF at the Cleveland Clinic between
January 2002 and December 2011. Study claims compli-
ance with Helsinki Declaration. Cleveland Clinic institu-
tional board review approved the study protocol and
determined that it meets criteria for waiver for consent.
Inclusion criteria
Adult patients with known history of IPF who presented
with possible AEX-IPF or new patients that eventually
were diagnosed to have AEX-IPF as an initial manifest-
ation of the disease and patients with full predefined in-
formation available in the electronic medical records at
the Cleveland Clinic for the following diagnoses: idio-
pathic pulmonary fibrosis and acute exacerbation of
idiopathic pulmonary fibrosis.
Exclusion criteria
Patients with missing information in the medical records,
and patients status post lung transplant.
Statistical methods used
Continuous measures were described as means, standard
deviations, and percentiles. Categorical measures were sum-
marized using frequencies and percentiles. The Pearson’s
chi-square test or Fisher’s exact test was used to assess the
associations between the binary groups and categorical
measures. The two sample T-test were used to evaluate
the relationship between binary groups and continuous
measures. All tests were performed at a significance level
of 0.05. SAS 9.3 software (SAS Institute, Cary, NC) was
used for all analyses.
Results
A total of 77 patients met the study inclusion criteria, of
which 37 were females and 40 were males. Of these pa-
tients, 47 (61 %) were diagnosed with AEX-IPF (Table 1).
Bronchoscopy with BAL was done in 38 % of all patients
(29 procedures), as well as 38 % in the subgroup of pa-
tients eventually diagnosed with AEX-IPF (18 procedures).
In 6 of these 29 procedures, bronchoscopy was performed
prior to administration of antibiotics.
Bronchoscopy was more likely to be performed in pa-
tients who were on cytotoxic medications, but it did not
Table 1 Table represents final diagnosis in IPF patients admitted
with acute respiratory failure. Two most common final diagnosis







Hypoglycemia and respiratory failure 1
COPD exacerbation 1
Pulmonary embolism 1
Transtracheal oxygen catheter related problem 1
Pneumomediastinum 1
Ischemic heart disease 1
Bronchogenic carcinoma 1
Total number of cases 77
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depend on gender, smoking history, prior steroid therapy
or any other patient characteristics (Table 2). Diagnosis
of infection was made when BAL, tracheal aspirate, spu-
tum culture or blood culture was found positive and not
considered to be a contaminant. Of the 14 patients who
were diagnosed with pulmonary infections, two had
fever on admission (p = 0.15), and 12 had white blood
count greater than 11.0 k/ul (p = 0.17) and a total of 57
out of 77 patients were started on broad spectrum anti-
biotics. Six patients had a BAL performed, but with only
one identified case of infection. In this one patient, BAL
was positive both for PJP and cytomegalovirus and blood
culture was positive for vancomycine resistant entero-
coccus (VRE). An additional patient had a BAL per-
formed which grew methicillin sensitive staphylococcus
aureus (MSSA), but the final diagnosis was AEX-IPF.
Both of these patients were treated with antibiotics prior
to BAL being performed. Tracheal aspirate cultures were
done for six patients (four of them had BAL done with
no growth), and one patient was positive for influenza A
virus. Sputum culture was performed in 26 patients, and
two patients grew Stenotrophomonas maltophilia (judged
to be contaminant) and Klebsiella pneumoniae respect-
ively. Blood cultures were done in 50 patients, and two pa-
tients grew VRE and staphylococcus hominis respectively
(latter was judged to be contaminant, Table 3). Of the
three patients who had BAL and sputum cultures done
at the same time, only one sputum culture was positive
for growth (Klebsiella pneumoniae) while the BAL did
not show evidence of infection. Mycoplasma IgM, urine
streptococcus pneumonia antigen and urine Legionella
antigen were checked in six, four, and twelve patients
respectively and were negative in all patients.
Univariate and multivariate analysis were performed with
predefined risk factors and final diagnosis of AEX-IPF and
pulmonary infection (Tables 4 and 5). Only prior to admis-
sion steroid use, which was defined ad daily prednisone in-
take 10–60 mg, was found to be significantly associated
with developing a pulmonary infection, where 10 out of 14
patients (71 %) on steroids were found to have an infection
versus only 21 out of 63 patients (33 %) patients who were
not on steroids (p = 0.024, OR 7.817, 95 % CI 1.31–46.64).
Overall mortality in our population cohort was 28.6 %, and
this was not significantly different amongst AEX-IPF pa-
tients (29.8 %), patients with pulmonary infection (28.5 %)
Table 2 Table represents association between IPF patient
characteristics on hospital admission and performance of
bronchoscopy with BAL. Two patients with missing data on BAL
performance were excluded
Bronchoscopy with BAL done
Factor No (N = 46) Yes (N = 29) Total (N = 75) P-value
Gender 0.97a
Female 22 (47.8 %) 14 (48.3 %) 36 (48.0 %)




Yes 23 (48.9 %) 15 (62.5 %) 37 (53.6 %)
No 23 (51.1 %) 9 (37.5 %) 32 (46.4 %)
Prior steroid use 0.85a
No 26 (56.5 %) 13 (54.2 %) 39 (55.7 %)




No 46 (100.0 %) 17 (73.9 %) 63 (91.3 %)




No 35 (76.1 %) 17 (68.0 %) 52 (73.2 %)




No 43 (92.5 %) 23 (95.8 %) 60 (93.8 %)




No 36 (74.4 %) 18 (75.0 %) 47 (74.6 %)




No 16 (23.1 %) 8 (33.3 %) 17 (27.0 %)
Yes 30 (76.9 %) 16 (66.7 %) 46 (73.0 %)
ICU care 0.70a
No 29 (63.0 %) 17 (58.6 %) 46 (61.3 %)
Yes 17 (37.0 %) 12 (41.4 %) 29 (38.7 %)
Procalcitonin 0.60c
Mean (SD) 0.4 (0.8) 0.7 (0.6) 0.6 (0.7)




Table 3 Table represents microbiologic data obtained in the
study patients with IPF presenting with acute respiratory failure
and the positivity rate of the cultures
Type of culture Total (N = 77)
No Yes
Tracheal aspirate obtained 71 (92.1 %) 6 (7.9 %)
Growth on tracheal aspirate 76 (98.7 %) 1 (1.3 %)
Sputum culture obtained 51 (65.3 %) 26 (34.7 %)
Sputum culture positive for infection 75 (97.4 %) 2 (2.6 %)
Blood cultures obtained 27 (34.2 %) 50 (65.8 %)
Blood culture positive 75 (97.4 %) 2 (2.6 %)
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and patients with respiratory failure due to other causes
(25 %).
Discussion
Today, BAL technique is standardized [9] and it is often
used in the workup of AEX-IPF. Pesci et al. [10] recom-
mended that BAL should be considered in all IPF pa-
tients with suspected infection, malignancy or AEX-IPF.
Papanikolaou et al. [11], as well as Wuyts et al. [12] state
that BAL should be performed if the patient can tolerate
the procedure (DLCO > 30 % and PaO2 > 75 mmHg on
supplemental oxygen). The official ATS/ERS/JRS/ALAT
statement on pulmonary fibrosis does not give clear rec-
ommendations on the diagnostic workup for AEX-IPF
[13]. Overall BAL is widely considered a part of the diag-
nostic workup of a patient with IPF presenting with acute
respiratory failure, and is performed for nearly every eval-
uated patient that can tolerate it, although the predictive
usefulness and safety of the procedure has not been fully
elucidated.
Several other potentially useful roles of the BAL were
recently entertained. It has been shown that BAL sam-
ples from some AEX-IPF patients have increased level of
pepsin [14] and that treatment with proton pomp inhibi-
tors might have a role in the prevention of exacerbations
in these selected patients [15]. This suggests that some
IPF exacerbations might be triggered by silent aspiration
and those patients do not need treatment with broad
spectrum antibiotics. Song et al. showed that measuring
percentage of neutrophils in the BAL fluid can be a use-
ful tool to discriminate between pulmonary infection
and AEX-IPF but this practice has not been routinely
recommended and needs further investigation [16]. If
clinical suspicion for drug induced alveolitis or other
specific etiology, BAL can be performed tailored to that
specific diagnoses, in case the BAL fluid differential
count would change the management. For AEX-IPF or
infection, no such strong data is available, and one
should not base treatment decisions on BAL fluid differ-
ential count. In addition, the percentage of neutrophils
in the BAL fluid is increased during the AEX-IPF epi-
sodes compared to stable patients with IPF and controls,
which makes this data less reliable to exclude infectious
process [17, 18]. It has also been shown that BAL is not
a benign procedure and in fact, is an independent risk
factor for IPF exacerbation [19–22]. In a retrospective
study it was shown that the risk of AEX-IPF is elevated
within 30 days after BAL (RR 4.12; 95 % CI 1.03–12.2),
moreover the relative risk of developing AEX-IPF after
second or later BAL procedures was estimated to be
considerably higher (RR 9.10; 95 % CI 2.27–26.98). In a
recent review of the utility of BAL in diffuse parenchy-
mal lung diseases, the role of BAL was critical in the
diagnosis of opportunistic infections in patients treated
Table 4 Multivariable association between final diagnosis of AEX-IPF and patient risk factors. No statistically significant association
was revealed
Effect Odds ratio 95 % CI P-value
Steroids on admission: No vs Yes 2.998 0.881 10.206 0.079
Cytotoxic agents on admission: No vs Yes 1.054 0.156 7.117 0.96
Antibiotics on admission: No vs Yes 1.372 0.352 5.344 0.65
Sputum culture positive: No vs Yes 4.007 0.235 68.279 0.34
Elevated WBC on admission: No vs Yes 1.22 0.37 4.022 0.74
Fever on admission: Yes vs No 1.112 0.086 14.313 0.94
Tachycardia on admission: No vs Yes 1.454 0.396 5.331 0.57
Tachypnea on admission: Yes vs No 1.814 0.472 6.978 0.39
Table 5 Multivariable association between final diagnosis of pulmonary infection and patient risk factors
Effect Odds ratio 95 % CI P-value
Steroids on admission: Yes vs No 7.817 1.31 46.64 0.024*
Cytotoxic agents on admission: No vs Yes 2.407 0.196 29.524 0.49
Antibiotics on admission: Yes vs No 2.051 0.308 13.65 0.46
Sputum culture positive: Yes vs No 2.427 0.148 39.718 0.53
Elevated WBC on admission: Yes vs No 1.474 0.268 8.094 0.66
Fever on admission: Yes vs No 1.651 0.109 25.021 0.72
Tachycardia on admission: No vs Yes 1.552 0.201 11.956 0.67
Tachypnea on admission: Yes vs No 1.088 0.142 8.362 0.94
*Patients who were on steroids on admission were more likely diagnosed with pulmonary infection then patients who were not on steroids (p = 0.024)
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with immunosuppressive therapy [23], but is not neces-
sary in all patients.
In this retrospective study to assess the diagnostic
value of bronchoscopy and BAL performed in the work
up for suspected AEX-IPF cases we identified patients
with a known history of IPF, who presented with acute
respiratory failure and were being evaluated for AEX-
IPF. AEX-IPF and pulmonary infection were the two
most common final diagnoses and a minority of patients
were found to have other cardiovascular and pulmonary
conditions as a cause of their acute decompensation.
The diagnosis of AEX-IPF was not associated with any
of the predefined patient characteristics or measurable
factors (such as gender, tobacco exposure or vital signs
on admission). 38 % of patients had a bronchoscopy with
BAL performed as a part of the diagnostic workup and it
was more likely to be performed in patients receiving
cytotoxic agents. One can only speculate that these pa-
tients were considered high risk for pulmonary infection
and BAL was done due to high pretest probability. There
was no other significant difference between two groups,
which allowed further statistical analysis.
It is worth noting that in our cohort only three of 14
patients who had a final diagnosis of pulmonary infec-
tion had microbiological confirmation, one each from
BAL and blood culture, tracheal aspirate culture and
sputum culture. Only prior to admission steroid use was
associated with a final diagnosis of pulmonary infection.
In most cases, diagnosis of infection was made on the
basis of physical examination, clinical history, labora-
tory/imaging data and clinician judgment. It seems BAL
is most helpful when performed in patients with high
pretest probability such as patients on steroids or im-
munosuppressive agents.
Most of our patients were started on broad spectrum
antibiotics on admission prior to BAL and completed
the course despite negative microbiological workup. We
believe this is a common scenario in other centers too
and shows that BAL fluid analysis does not change the
treatment strategy. In our cohort bronchoscopy with
BAL had little influence on the management of the pa-
tients which might suggest that patients who present
with possible AEP-IPF versus pulmonary infection should
be empirically treated with broad spectrum antibiotics and
that bronchoscopy with BAL should be performed in
selected cases only based on clinical judgment and case
scenario, such as current use of steroids or other immuno-
suppressive agents.
Limitations of our study include relatively small sam-
ple size, single center participation and the retrospective
nature of the study. Treatment selection biases as well
as reliance on expert opinion in many cases for final
Fig. 1 Suggested algorithm for the management of patients with IPF who present with acute respiratory failure. IPF-idiopathic pulmonary fibrosis,
BAL-bronchoalveolar lavage, CTA-computer tomographic angiography, CUS-compression ultrasonography, PE-pulmonary embolism, BNP-brain
natriuretic peptide, CHF-congested heart failure, AEX-IPF-acute exacerbation of idiopathic pulmonary fibrosis
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diagnosis should be considered as well. Cleveland Clinic
is a tertiary care center and a patient selection bias also
could not be excluded. Our practice is not to use immu-
nosuppressants for maintenance treatment of IFP pa-
tients, so our findings may not be translatable in other
institutions who have not adopted this practice. Most of
our patients were started on antibiotics before BAL could
be performed and our conclusions may not be generalized
to patient in whom BAL with fluid differential and cul-
tures are done first.
Therefore, based on our findings in this study, we
propose the following algorithm in the management of IPF
patients presenting with acute respiratory failure (Fig. 1).
IPF patients presenting with acute respiratory failure
should first be evaluated for identifiable causes for their
deterioration including but not limited to pulmonary in-
fection, congestive heart failure decompensation, aspir-
ation, pulmonary embolism, drug induced complications,
and AEX-IPF based on clinical presentation. We suggest
that all patients should be initiated on broad spectrum an-
tibiotics upon presentation (including coverage for PJP if
clinically indicated), ideally after blood, sputum and, in se-
lect cases, BAL cultures are obtained. One should not wait
for culture results to initiate antibacterial therapy, but it
should be used for de-escalation strategy. If BAL cultures
are routinely obtained after initiation of antibiotic therapy,
false negative results are likely and make further decisions
for de-escalation a guess. Accordingly, we do not suggest
BAL for all patients. If BAL can be safely obtained before
the antibiotics are given, the diagnostic workup might be
different and not reflected by our algorithm as most of our
patients did get antibiotics before the BAL. If a non-
infectious cause is identified, such as pulmonary embolism
or pneumothorax, then antibiotics can be safely discon-
tinued. Bronchoscopy with BAL should be performed in
immunocompromised patients on steroids and other cyto-
toxic drugs, but also for selected patients with worsening
respiratory failure despite broad spectrum antibiotics and
inconclusive or unrevealing workup. In a retrospective
study by Song et al., BAL and/or endotracheal aspiration
were performed in 52.8 % of 461 patients highlighting the
fact that in real life scenarios BAL is not performed for
various reasons despite the universal recommendation and
that our algorithm will be suitable for these cases [16]. It is
based on small sample size, retrospective data and single
center experience and should be used with these limita-
tions in mind.
Conclusions
Our data support that the decision regarding perform-
ance of BAL should be used in conjunction with other
historical and clinical data, and in select cases clinician
should be able to forego bronchoscopy. Exclusion of in-
fection in our IPF patient cohort was mostly based on
factors other than diagnostic bronchoscopy with BAL.
Prior to admission steroid use was associated with a final
diagnosis of pulmonary infection. Based on our results
we suggested an algorithm for management of IPF pa-
tients presenting with acute respiratory failure.
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